title: Positive KL-6 mucin expression combined with decreased membranous beta-catenin expression indicates worse prognosis in colorectal carcinoma.
abstract: Interaction of MUC1 with beta-catenin plays a significant role in tumor progression and invasion. However, the clinical significance of coexpression of MUC1 and subcellular beta-catenin expression in colorectal carcinoma remains unclear. The present study evaluated the clinicopathological significance of their combined expression for predicting prognosis. Seventy-seven colorectal carcinomas were subjected to immunohistochemical staining with anti-MUC1 KL-6 mucin and anti-beta-catenin monoclonal antibody. Positive KL-6 mucin expression was correlated with decreased membranous beta-catenin expression (P=0.022), while no correlation was found between positive KL-6 expression and nuclear beta-catenin expression (P=0.142). Preservation of membranous beta-catenin expression was detected in 35 cases (45.5%) and decreased membranous beta-catenin expression was found in 42 cases (54.5%). Negative KL-6 expression was detected in 31 cases (41.3%) and positive expression was seen in 46 cases (59.7%). Combined positive KL-6 expression and decreased membranous beta-catenin expression was found in 30 patients (39.0%), whose survival was significantly worse than that of patients with other expression patterns for these two molecules (53.3 vs. 84.4%, P=0.005). Multivariate analysis showed that this combination was as an independent predictor of survival. We concluded that the combined pattern of positive KL-6 expression and decreased membranous beta-catenin expression by colorectal carcinoma is a useful biomarker for distinguishing a subgroup of patients with a worse prognosis.
authors.affiliation: Minimally Invasive Surgery Center, Changzheng Hospital, Second Military Medical University, Shanghai, P.R. China.
authors.forename: Wei
authors.initials: W
authors.lastname: Zhang
authors.forename: Wei
authors.initials: W
authors.lastname: Tang
authors.forename: Yoshinori
authors.initials: Y
authors.lastname: Inagaki
authors.forename: Ming
authors.initials: M
authors.lastname: Qiu
authors.forename: Huan-Li
authors.initials: HL
authors.lastname: Xu
authors.forename: Xun
authors.initials: X
authors.lastname: Li
authors.forename: Yasuhiko
authors.initials: Y
authors.lastname: Sugawara
authors.forename: Hirokazu
authors.initials: H
authors.lastname: Nagawa
authors.forename: Munehiro
authors.initials: M
authors.lastname: Nakata
authors.forename: Norihiro
authors.initials: N
authors.lastname: Kokudo
mesh_terms: D000230:Adenocarcinoma / Q000378:metabolism* / Q000401:mortality / Q000473:pathology; D014408:Biomarkers, Tumor / Q000032:analysis*; D002462:Cell Membrane / Q000378:metabolism; D015179:Colorectal Neoplasms / Q000378:metabolism* / Q000401:mortality / Q000473:pathology; D005260:Female; D015870:Gene Expression; D006801:Humans; D007150:Immunohistochemistry; D053208:Kaplan-Meier Estimate; D008297:Male; D018396:Mucin-1 / Q000096:biosynthesis*; D011379:Prognosis; D051176:beta Catenin / Q000096:biosynthesis*
chemical_list: D014408:Biomarkers, Tumor; C060192:MUC1 protein, human; D018396:Mucin-1; D051176:beta Catenin